You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses.
Wall Street analysts are bullish on the firm's cell selection platform technology, which could find a total addressable market of more than $20 billion.
The Emeryville, California-based instrument maker expects to raise $178.2 million after offering 8.1 million shares at $22 per share.
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
The firm is offering approximately 3 million shares and said it may use a portion of the proceeds to acquire, license, or invest in complementary businesses or products.
The offering of common stock will be the second for Twist this year and the third since the company made its initial public offering in October 2018.
The Seattle-based immune sequencing firm will not receive any proceeds from the sale of the shares.
The immune sequencing firm announced preliminary full-year 2019 revenues in the range of $84 million to $85 million, an increase of approximately 52 percent.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.